The proven involvement of cytokines in the pathophysiology of Inflammatory Bowel Disease (IBD) has led to the development of powerful, selective, anticytokine drugs, so called biologics. Biologic therapies for IBD like Infliximab have revolutionized the treatment of patients with Crohn's disease and have begun to have an impact on therapy for refractory ulcerative colitis.
Calabrese, E., Pallone, F. (2008). New biologic therapies in patients with Inflammatory Bowel Disease [Nuovi farmaci biologici nelle Malattie Infiammatorie Croniche Intestinali]. GIORNALE ITALIANO DI ENDOSCOPIA DIGESTIVA, 31(4), 303-309.
New biologic therapies in patients with Inflammatory Bowel Disease [Nuovi farmaci biologici nelle Malattie Infiammatorie Croniche Intestinali]
CALABRESE, EMMA;PALLONE, FRANCESCO
2008-01-01
Abstract
The proven involvement of cytokines in the pathophysiology of Inflammatory Bowel Disease (IBD) has led to the development of powerful, selective, anticytokine drugs, so called biologics. Biologic therapies for IBD like Infliximab have revolutionized the treatment of patients with Crohn's disease and have begun to have an impact on therapy for refractory ulcerative colitis.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
